Showing 2311-2320 of 5268 results for "".
- In Phase 2b Trial, Spesolimab Meets Endpoints for Prevention of Generalized Pustular Psoriasis (GPP) Flareshttps://practicaldermatology.com/news/in-phase-2b-trial-spesolimab-meets-endpoints-for-prevention-of-generalized-pustular-psoriasis-gpp-flares/2461529/Spesolimab (Boehringer Ingelheim), an anti-interleukin-36 receptor antibody, met its primary and key secondary endpoint, demonstrating it can prevent flares in patients with generalized pustular psoriasis (GPP) and provide sustained symptom management up to 48 weeks, according to results of the P
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Elsevier Introduces First 3D Human Anatomy Model in Different Skin Toneshttps://practicaldermatology.com/news/elsevier-introduces-first-3d-human-anatomy-model-in-different-skin-tones/2461516/Elsevier is rolling out the newest edition of its 3D anatomy teaching platform, Complete Anatomy 2023, which will feature the most expansive set of skin tone selections ever available in global health education.
- Phase 2b Study: Arcutis' Roflumilast Cream Shows Sustained Efficacy in Adults with Chronic Plaque Psoriasishttps://practicaldermatology.com/news/pgase-2b-study-arcutis-roflumilast-cream-shows-sustained-efficacy-in-adults-with-chronic-plaque-psoriasis/2461513/Arcutis' roflumilast cream showed sustained efficacy with clearance for median of 10 Months in adults with chronic plaque psoriasis, according to an open label Phase 2 long-term safety study presented at the Winter Clinical dermatology meeting. Roflumilast cream
- Twenty New Products Earn NPF Seal of Recognitionhttps://practicaldermatology.com/news/twenty-new-products-earn-npf-seal-of-recognition/2461512/Twenty new products have earned the National Psoriasis Foundation’s Seal of Recognition. Each of these 20 products passed the same rigorous application, review, and approval process as the other 45 products that comprise the
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis,
- Investigational Topical Peptide May Help Tame Eczemahttps://practicaldermatology.com/news/investigational-topical-peptide-may-help-tame-eczema/2461503/A new investigational topical peptide may can block inflammatory signaling in a preclinical model of atopic dermatitis – eczema, researchers at Vanderbilt University Medical Center (VUMC) report. Treatment for severe cases of eczema includes immunosuppressive drugs
- Report: More Physician Turnover, Use of Extenders in Private Equity-backed Dermatology Practiceshttps://practicaldermatology.com/news/report-more-physician-turnover-use-of-extenders-in-private-equity-backed-dermatology-practices/2461502/There’s more physician turnover and greater reliance on physician assistants in dermatology practices that sold to private equity, a new study shows. In the study of 213 private equity-acquired practices in dermatology, ophthalmology, and gastroenterology and 995 physic
- Algae May Enhance Skin Regeneration and Wound Healing: Studyhttps://practicaldermatology.com/news/algae-may-enhance-skin-regeneration-and-wound-healing-study/2461496/Euglena gracilis may enhance skin regeneration to speed wound healing, according to new research. Investigators developed a system based on microvesicles that bud from the cell surface of Euglena gracilis, a freshwater single-celled green algae, and conta